Veliparib (ABT-888)

製品コードS1004 別名:NSC 737664

Veliparib (ABT-888)化学構造

分子量(MW):244.29

Veliparib (ABT-888) は一種の有効なPARP1とPARP2阻害剤で、無細胞試験でKi値が5.2 nM と2.9 nMに分かれて、SIRT2に活性を表しません。臨床3期。

サイズ 価格(税別) 在庫  
JPY 25896.00 あり
JPY 19920.00 あり
JPY 61420.00 あり

文献中の使用例(40)

カスタマーフィードバック(9)

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明 Veliparib (ABT-888) は一種の有効なPARP1とPARP2阻害剤で、無細胞試験でKi値が5.2 nM と2.9 nMに分かれて、SIRT2に活性を表しません。臨床3期。
特性 Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
ターゲット
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
体外試験

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 MlftT4lv[XOnIFHzd4F6 NIS0OJc{OCCvaX6= MVjJcohq[mm2aX;uJI9nKFCDUmCxJJdqfGhiRVO1NEBw\iByLkCwNkDPxE1? MXyxPVg5QDd4MB?=
Jurkat MnHpT4lv[XOnIFHzd4F6 MmfKPVYhcA>? NFHlWYZFVVOR M2XvcWlvcGmkaYTpc44hd2ZiUFHSVFEh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IIfpeIghTUN3MDDv[kA{KM7:TR?= M1PGUFI{QDVyMUm5
Capan1 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[3NkBp NF7URYdFVVOR MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLSR2EzKGenbnWgcZV1[XSnZDDoeY1idiCFYYDhclEh[2WubIOge4l1cCCLQ{WwJI9nKDN7Lkeg{txO MV:yOFM6QDN6Mx?=
DT40 M2LhO2N6fG:2b4jpZ{BCe3OjeR?= MVu3NkBp M3;YWGROW09? NGj0OIxEgXSxdH;4bYNqfHliYXfhbY5{fCClaHnjb4VvKEKUQ1GyMYRm\mmlaXXueEBFXDRyIHPlcIx{ Mlq5NlQ6OjJ3OEe=
ML-1 NX\zdGh3SXCxcITveIlkKEG|c3H5 NXi2N5VJOi53IN88US=> M1X2N|I1KGh? NX7VOXRqTE2VTx?= NX;nc4g{W3mwZYLnbZN1cWOjbHz5JIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|IHnuJG1NNTFiY3XscJM> MlXpNlQ5QTVzM{W=
HCT-116 NIizbINMcW6jc3WgRZN{[Xl? NVjNVJU1OC53IN88US=> NV\Q[odjOjRiaB?= M{LuNXBCWlBiYXP0bZZqfHliZHXjdoVie2W| M2nT[VI{ODV2MkGz
UM-SCC1 MYHDfZRwfG:6aXOgRZN{[Xl? MVmxNEDPxE1? MYeyOEBp MlyxVoVlfWOnczD0bIUh[2WubDD2bYFjcWyrdIm= M3fGXlIyQTF{NkKw
FaDu MkPWR5l1d3SxeHnjJGF{e2G7 NGLPVY0yOCEQvF2= M{L0OFI1KGh? NIPITY9T\WS3Y3XzJJRp\SClZXzsJJZq[WKrbHn0fS=> MWKyNVkyOjZ{MB?=
PC-3 NHrr[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fqOlExKM7:TR?= M1u2[Wlv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnjpZol1cW:wIHnuJINwdG:weTDmc5Ju[XSrb39CpC=> Mni0NlE2PzF7MUK=
EoL-1-cell MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITxNHdKSzVyPUGuNFc6QCEQvF2= NEm4U25USU6JRWK=
NCI-SNU-5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTpTWM2OD1|LkGyPFQyKM7:TR?= NH\KcXJUSU6JRWK=
BV-173 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj5TWM2OD13LkS1OFA6KM7:TR?= NYryTFZvW0GQR1XS
HCC1806 M1jIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\C[W1XUUN3ME21Mlc2OTd|IN88US=> M4rBUnNCVkeHUh?=
COLO-680 NIrLVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2frVmlEPTB;Nj6yNVQxPiEQvF2= NXm3bllzW0GQR1XS
HCC2218 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jIVWlEPTB;Nz63PVcxPCEQvF2= M1rjPHNCVkeHUh?=
SK-MEL-24 NVryfIY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTOTWM2OD15LkixPVI1KM7:TR?= MY\TRW5ITVJ?
NCI-H720 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRThwNEO2NFMh|ryP MmX6V2FPT0WU
KASUMI-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrSRVNKSzVyPUiuPFkzPjZizszN MVzTRW5ITVJ?
HAL-01 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTlwOEi2NkDPxE1? M{nRO3NCVkeHUh?=
CAL-33 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TGPGlEPTB;MUCuOFM1KM7:TR?= NXHB[Yx4W0GQR1XS
SK-MEL-1 M{fXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTJXpd1UUN3ME2xNk41PjZ|IN88US=> MUDTRW5ITVJ?
Ramos-2G6-4C10 NUPYd4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Poe2lEPTB;MUKuOFc2OiEQvF2= MnLaV2FPT0WU
KY821 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PrdmlEPTB;MUKuOFg2KM7:TR?= NH;pVpBUSU6JRWK=
HEC-1 MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\zTWM2OD1zMj65NVk3KM7:TR?= M1y5eXNCVkeHUh?=
SK-NEP-1 NXfINm5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\KbmhKSzVyPUGzMlE3PiEQvF2= MkH0V2FPT0WU
MN-60 NX\zNG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTRTWM2OD1zMz61N|g6KM7:TR?= MVHTRW5ITVJ?
DU-145 NYjObZM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fycGlEPTB;MUOuPVA2OyEQvF2= MlLnV2FPT0WU
EW-3 NXrtclAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\PdGlEPTB;MUSuOVU3PSEQvF2= NInUR4lUSU6JRWK=
OS-RC-2 M1jaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PhRmlEPTB;MUWuPVU5QSEQvF2= M4DZdnNCVkeHUh?=
RPMI-8226 M4rLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXniNIcyUUN3ME2xOk4zODR{IN88US=> NWD6NFVNW0GQR1XS
ChaGo-K-1 NV3rW4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTiZndJUUN3ME2xOk42OzJ3IN88US=> MUDTRW5ITVJ?
DEL M{j0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfDR2ZKSzVyPUG2MlY4OTdizszN Ml7iV2FPT0WU
GP5d NUTRWoJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLWU5FKSzVyPUG3MlA2OyEQvF2= M{WxTXNCVkeHUh?=
COLO-668 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF5Lk[yPVQh|ryP NFLqcGRUSU6JRWK=
H9 NFfMRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr5XGdKSzVyPUG4MlI5OzNizszN MVXTRW5ITVJ?
NKM-1 NGnXT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF6LkWxNVkh|ryP MXrTRW5ITVJ?
KYSE-150 MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITvWHhKSzVyPUG4Mlk6QDZizszN M1vY[nNCVkeHUh?=
Daoy MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HMSmlEPTB;MUmuOVY1QSEQvF2= M{nVVXNCVkeHUh?=
ECC10 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvPb5hKSzVyPUKwMlc1PTVizszN NHXyVoxUSU6JRWK=
A388 M{PZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJzLkmwPVEh|ryP M2HWb3NCVkeHUh?=
MHH-NB-11 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3uUJdHUUN3ME2yN{4yOzZ|IN88US=> MWXTRW5ITVJ?
HCC1937 M4qxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC0TWM2OD1{ND63OFYh|ryP Mnq1V2FPT0WU
TGBC11TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PtOWlEPTB;MkWuOlg3OyEQvF2= MnvIV2FPT0WU
CTV-1 NU\5fmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXOS25QUUN3ME2yOU45QTZ7IN88US=> NG\nZ|FUSU6JRWK=
NCI-H2029 MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJ4LkSyN|gh|ryP M{K0PXNCVkeHUh?=
HLE Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICxfWVKSzVyPUK3MlA2PCEQvF2= MnLjV2FPT0WU
NCI-H1693 M2XxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi3S4JlUUN3ME2yO{4zQDl6IN88US=> M2LRUHNCVkeHUh?=
HCC70 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnMRoZQUUN3ME2yO{44OjR4IN88US=> MVLTRW5ITVJ?
BEN NGjOeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnEfINKSzVyPUK3Mlk2PjZizszN NGDtXW1USU6JRWK=
LB771 NETXepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ITWM2OD1{OD64N|c{KM7:TR?= M3f5d3NCVkeHUh?=
697 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjFToZKSzVyPUK5MlAzOzVizszN NEWxfpZUSU6JRWK=
LU-139 M4rodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\kdGxKSzVyPUK5MlM4PDhizszN NEPhfIlUSU6JRWK=
EW-13 M4PNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHkTWM2OD1{OT6zPFE1KM7:TR?= NWT1SZVRW0GQR1XS
MOLT-13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H3PWlEPTB;MkmuN|gyPCEQvF2= NVHifmdIW0GQR1XS
L-363 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLJTWM2OD1{OT60O|k5KM7:TR?= NEPvZodUSU6JRWK=
EM-2 NH\rT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[yUWlEPTB;MkmuOFkxOSEQvF2= M1HGVnNCVkeHUh?=
RS4-11 NXv6bGY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP6TWM2OD1|MD60NlQyKM7:TR?= NEPLPJpUSU6JRWK=
A2780 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PkXmlEPTB;M{CuO|Q2PyEQvF2= Mn22V2FPT0WU
KU812 NVn1dVhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjwWXlKSzVyPUOyMlM3PDJizszN M3frcHNCVkeHUh?=
COLO-684 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrnTWM2OD1|Mz6zOVk6KM7:TR?= MlziV2FPT0WU
MFE-280 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN|LkO4PFkh|ryP NHf5XY9USU6JRWK=
KG-1 NGHZUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXztUohYUUN3ME2zN{43ODBzIN88US=> M{DsVnNCVkeHUh?=
JVM-3 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID1dXdKSzVyPUO1MlU5PjhizszN NHO3d2lUSU6JRWK=
MV-4-11 M2n0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX3U4l1UUN3ME2zOU45PDl7IN88US=> M3vnTnNCVkeHUh?=
LAMA-84 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3BSHlKSzVyPUO2Mlc{PDVizszN Mn:3V2FPT0WU
MOLT-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPoRXdwUUN3ME2zOk46PTJizszN M3rTdXNCVkeHUh?=
H4 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rZfWlEPTB;M{euOVY4KM7:TR?= NHrmenRUSU6JRWK=
T47D MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LNb2lEPTB;M{euO|AyQCEQvF2= MlXMV2FPT0WU
CAL-54 M3u5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnuO3ZNUUN3ME2zO{46PjZizszN MVPTRW5ITVJ?
SW982 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;XOWlEPTB;M{iuNFk6QCEQvF2= Ml;BV2FPT0WU
IGROV-1 NITsb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;pT5g1UUN3ME2zPU4{OzB2IN88US=> NX:0RYtLW0GQR1XS
NB14 M1LyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRyLkewN|Eh|ryP M13MZ3NCVkeHUh?=
HCC1187 NGDwc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPvR3RrUUN3ME20NU4zPzdzIN88US=> MlPiV2FPT0WU
SBC-1 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D6TGlEPTB;NEGuN|A3OyEQvF2= MoK1V2FPT0WU
KARPAS-45 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXVTINrUUN3ME20NU41QDF6IN88US=> MWrTRW5ITVJ?
MOLT-4 NXz0[YU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\DTWM2OD12Mj6yOVM5KM7:TR?= MYDTRW5ITVJ?
JVM-2 NIHicGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorETWM2OD12Mj65NlA4KM7:TR?= MXHTRW5ITVJ?
A4-Fuk MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vXe2lEPTB;NEOuOVY6OSEQvF2= NGfEWoZUSU6JRWK=
MDA-MB-361 MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTZTWM2OD12Mz64OFE1KM7:TR?= NHTIVJFUSU6JRWK=
BALL-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T5eGlEPTB;NEOuPVU{OiEQvF2= NVXBdZBTW0GQR1XS
T98G MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\TdmlEPTB;NESuPFUyPyEQvF2= NX3QfG9WW0GQR1XS
Mo-T M2jRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnvTWM2OD12NT62N|g6KM7:TR?= M4H3OHNCVkeHUh?=
MHH-PREB-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fobGlEPTB;NEWuO|U5PSEQvF2= MlL5V2FPT0WU
ALL-PO NVX6WZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITERYRKSzVyPUS3MlM4QTFizszN MWjTRW5ITVJ?
NCI-H510A MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTR5LkmwN|Qh|ryP MVnTRW5ITVJ?
ML-2 MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPYTWM2OD12OT63PFU3KM7:TR?= NUnlOnZ2W0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

お薦めの試験操作(参考用のみ)

動物試験:

[1]

+ 展開
  • 動物モデル: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • 製剤: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • 投薬量: ~25 mg/kg
  • 投与方法: Orally administered
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
0.5% methylcellulose+0.2% Tween 80
5 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 244.29
化学式

C13H16N4O

CAS No. 912444-00-9
保管
別名 NSC 737664

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01445522 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 3, 2008 Phase 1
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT02723864 Recruiting Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 22, 2016 Phase 1
NCT00994071 Completed Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 22, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PARP信号経路図

PARP Inhibitors with Unique Features

相関PARP製品

Tags: Veliparib (ABT-888)を買う | Veliparib (ABT-888) ic50 | Veliparib (ABT-888)供給者 | Veliparib (ABT-888)を購入する | Veliparib (ABT-888)費用 | Veliparib (ABT-888)生産者 | オーダーVeliparib (ABT-888) | Veliparib (ABT-888)化学構造 | Veliparib (ABT-888)分子量 | Veliparib (ABT-888)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID